From: BriAnn Maxwell
To: Pharmacy Services

Subject: Fw: Review Nevada ffs state medicaid board Date: Tuesday, December 8, 2020 4:43:54 PM

## PLEASE COSIDER MY COMMENT FOR THE MEETING . THANK YOU

Waheeda Jalal Office Manager Las Vegas Neuroscience and Pain Medicine Institute (702)220-5557 Phone (702)220-5565 Fax CONFIDENTIALITY NOTICE: This e-mail, including attachments, is for the sole use of the individual to whom it is addressed. This message is confidential and may contain information that is privileged, confidential and is exempt from disclosure under applicable law. Any unauthorized review, use, disclosure or distribution is prohibited. If you have received this e-mail in error, please notify the sender by reply e-mail and destroy this message and its attachments

---- Forwarded Message -----

From: BriAnn Maxwell <a href="mailto:knailto:k

To Whom it may concern,

I am writing to support placing Ubrelvy on Nevada State Medicaid Preferred's Drug List. Ubrelvy has been such a great addition to the acute treatment of migraine. My patients have waited long enough for a new class of medication.

In my personal experience, I have found Ubrelvy to be effective for many of my patients suffering from migraine. It has not only taken the edge off their pain but also the most bothersome symptoms. It's a non narcotic without having all the harsh side effects as the other acute treatments. My patients have been able to take Ubrelvy and continue on with their day at work. For many, they continue with their daily work activities, and its for these reasons I would like to see Ubrelvy on the preferred drug list.

I hope that you consider my comments for your review. Thank you for all your hard work.

Mouchir Harb M.D

Waheeda Jalal Office Manager Las Vegas Neuroscience and Pain Medicine Institute (702)220-5557 Phone (702)220-5565 Fax CONFIDENTIALITY NOTICE: This e-mail, including attachments, is for the sole use of the individual to whom it is addressed. This message is confidential and may contain information that is privileged,

confidential and is exempt from disclosure under applicable law. Any unauthorized review, use, disclosure or distribution is prohibited. If you have received this e-mail in error, please notify the sender by reply e-mail and destroy this message and its attachments